Cargando…
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...
Autores principales: | Dong, Wen, Lei, Pengfei, Liu, Xin, Li, Qin, Cheng, Xiangyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/ https://www.ncbi.nlm.nih.gov/pubmed/34804000 http://dx.doi.org/10.3389/fimmu.2021.686057 |
Ejemplares similares
-
Anaplastic lymphoma kinase-special immunity and immunotherapy
por: Guo, Ye, et al.
Publicado: (2022) -
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019) -
A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
por: Toor, Jugmohit S., et al.
Publicado: (2018) -
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
por: Huang, Hao
Publicado: (2018) -
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
por: Zhou, F., et al.
Publicado: (2023)